<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Korean J Thorac Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Korean J Thorac Cardiovasc Surg</journal-id><journal-title-group><journal-title>The Korean Journal of Thoracic and Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">2233-601X</issn><issn pub-type="epub">2093-6516</issn><publisher><publisher-name>The Korean Society for Thoracic and Cardiovascular Surgery</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25207222</article-id><article-id pub-id-type="pmc">4157475</article-id><article-id pub-id-type="doi">10.5090/kjtcs.2014.47.3.249</article-id><article-id pub-id-type="publisher-id">kjtcvs-47-249</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Research</subject></subj-group></article-categories><title-group><article-title>Efficacy and Safety of Dexmedetomidine for Postoperative Delirium in Adult Cardiac Surgery on Cardiopulmonary Bypass</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Park</surname><given-names>Jae Bum</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Bang</surname><given-names>Seung Ho</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Chee</surname><given-names>Hyun Keun</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Jun Seok</given-names></name><degrees>M.D.</degrees><xref ref-type="corresp" rid="c1-kjtcvs-47-249"/></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Song Am</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Shin</surname><given-names>Je Kyoun</given-names></name><degrees>M.D.</degrees></contrib><aff id="af1-kjtcvs-47-249">Department of Thoracic and Cardiovascular Surgery, Konkuk University Medical Center, Konkuk University School of Medicine, Korea</aff></contrib-group><author-notes><corresp id="c1-kjtcvs-47-249">Corresponding author: Jun Seok Kim, Department of Thoracic and Cardiovascular Surgery, Konkuk University Medical Center, Konkuk University School of Medicine, 120 Neungdong-ro, Gwangjin-gu, Seoul 143-729, Korea, (Tel) 82-2-2030-7593 (Fax) 82-2-2030-5009 (E-mail) <email>drjsk@kuh.ac.kr</email></corresp></author-notes><pub-date pub-type="ppub"><month>6</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>5</day><month>6</month><year>2014</year></pub-date><volume>47</volume><issue>3</issue><fpage>249</fpage><lpage>254</lpage><history><date date-type="received"><day>25</day><month>7</month><year>2013</year></date><date date-type="rev-recd"><day>19</day><month>11</month><year>2013</year></date><date date-type="accepted"><day>21</day><month>11</month><year>2013</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014 by The Korean Society for Thoracic and Cardiovascular Surgery. All rights Reserved.</copyright-statement><copyright-year>2014</copyright-year><license><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0">http://creativecommons.org/licenses/by-nc/3.0</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Background</title><p>Delirium after cardiac surgery is associated with serious long-term negative outcomes and high costs. The aim of this study is to evaluate neurobehavioral, hemodynamic, and sedative characteristics of dexmedetomidine, compared with the current postoperative sedative protocol (remifentanil) in patients undergoing open heart surgery with cardiopulmonary bypass (CPB).</p></sec><sec><title>Methods</title><p>One hundred and forty two eligible patients who underwent cardiac surgery on CPB between April 2012 and March 2013 were randomly divided into two groups. Patients received either dexmedetomidine (range, 0.2 to 0.8 &#x003bc;g/kg/hr; n=67) or remifentanil (range, 1,000 to 2,500 &#x003bc;g/hr, n=75). The primary end point was the prevalence of delirium estimated daily via the confusion assessment method for intensive care.</p></sec><sec><title>Results</title><p>When the delirium incidence was compared with the dexmedetomidine group (6 of 67 patients, 8.96%) and the remifentanil group (17 of 75 patients, 22.67%) it was found to be significantly less in the dexmedetomidine group (p&#x0003c;0.05). There were no statistically significant differences between two groups in the extubation time, ICU stay, total hospital stay, and other postoperative complications including hemodynamic side effects.</p></sec><sec><title>Conclusion</title><p>This preliminary study suggests that dexmedetomidine as a postoperative sedative agent is as sociated with significantly lower rates of delirium after cardiac surgery.</p></sec></abstract><kwd-group><kwd>1. Postoperative care</kwd><kwd>2. Dexmedetomidine</kwd><kwd>3. Complication</kwd><kwd>4. Thoracic surgery</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Postoperative delirium is generally known to develop in up to 57% of cardiac-surgery patients [<xref rid="b1-kjtcvs-47-249" ref-type="bibr">1</xref>]. Given this condition&#x02019;s high incidence rate, the consequences of delirium place a considerable burden on both patients and medical staff because of increased morbidity, higher mortality rates, incomplete functional cognitive recovery, prolonged hospitalization, and increased costs of long-term treatment [<xref rid="b2-kjtcvs-47-249" ref-type="bibr">2</xref>&#x02013;<xref rid="b4-kjtcvs-47-249" ref-type="bibr">4</xref>]. A number of studies have reported that 32% to 84% of delirium patients go unrecognized by the relevant clinical staff [<xref rid="b5-kjtcvs-47-249" ref-type="bibr">5</xref>], and the causes of postoperative delirium have not yet been identified. The known probable risk factors of delirium after cardiac surgery include advanced age, preexisting cognitive decline, atrial fibrillation, perioperative medications, previous delirium, and other metabolic disorders [<xref rid="b6-kjtcvs-47-249" ref-type="bibr">6</xref>]. Among them, major surgery including cardiac operations may increase the risk of delirium due to intricacy of the surgical procedure, administration of perioperative anesthetic and other pharmacological substances, and postoperative complications [<xref rid="b7-kjtcvs-47-249" ref-type="bibr">7</xref>,<xref rid="b8-kjtcvs-47-249" ref-type="bibr">8</xref>]. We hypothesized that the administration of dexmedetomidine (highly selective and potent &#x003b1;-2 adrenergic agonist with sedative and analgesic properties) may be associated with a lower incidence of delirium by pharmacological action. It produces sedation with modest analgesic and possible anti-delirium effects with minimal respiratory depression [<xref rid="b9-kjtcvs-47-249" ref-type="bibr">9</xref>,<xref rid="b10-kjtcvs-47-249" ref-type="bibr">10</xref>]. The present study was aimed at the investigation of the postoperative sedative effects of dexmedetomidine associated with a lower incidence of delirium, compared with the current postoperative sedative protocol (remifentanil) in patients undergoing open heart surgery with cardiopulmonary bypass (CPB). The primary endpoint was the proportion of patients in each group who developed postoperative delirium. Secondary endpoints included intubation time, length of stay in the intensive care unit (ICU), total length of hospitalization, and use of additional rescue medications.</p></sec><sec sec-type="methods"><title>METHODS</title><sec sec-type="methods|subjects"><label>1)</label><title>Study design and patients</title><p>All patients undergoing cardiac surgery are prospectively registered in Konkuk University Medical Center. These registries contain baseline characteristics of patients, perioperative evaluation data, and results or other complications of surgery. All patients fulfilling the inclusion and exclusion criteria and hospitalized for elective open heart surgery were eligible for this study. The study was approved by Konkuk University Medical Center&#x02019;s independent institutional review board, and informed consent was obtained from each patient. A total of 370 patients underwent cardiac surgery from April 2012 to March 2013. We excluded patients who had re-do and emergency surgery, severe pulmonary or systemic disease, left ventricular ejection fraction&#x0003c;40%, pre-existing renal dysfunction (serum creatinine level&#x0003e;2.0 mg/dL), and documented preoperative dementia, Parkinson disease, or recent stroke, and who were older than 90 years or younger than 17 years of age. In addition, patients who had psychotropic medications, evidence of progressed heart block, and surgery requiring deep hypothermic circulatory arrest involving thoracic aorta were also excluded. Among them, 142 patients who underwent cardiac surgery on CPB were enrolled in this trial. These eligible patients were randomly assigned to receive either dexmedetomidine (n=67) or remifentanil (n=75).</p></sec><sec sec-type="methods"><label>2)</label><title>Intraoperative procedures</title><p>Anesthesia for the operation was initiated according to the standardized protocol in both groups, including induction with propofol, fentanyl, and rocuronium, and maintenance with fentanyl and inhalation agents like sevoflurane. Surgical procedures were approached via either median sternotomy or right thoracotomy in conjunction with CPB. Right thoracotomy was performed on patients of atrioventricular valve diseases. In thoracotomy, we mostly used the femoral artery and vein or the right internal jugular vein as vascular access for CPB. All patients received standardized CPB management in the same manner. The protocol for CPB included moderate hypothermia (range, 26&#x000b0;C to 30&#x000b0;C) and flows initiated at the rate of 60 mL/kg/min, and was adjusted according to the state of hemodilution and core temperature. Patients were weaned from CPB when their rectal temperature reached 35&#x000b0;C. All patients were monitored with routine cardiac hemodynamic monitoring, including transesophageal echocardiography and pulmonary artery catheter. Bispectral index score (BIS) was also used to estimate the depth of anesthesia by means of an Aspect-3000 BIS monitor. The patients were transferred to, intubated in, and ventilated in cardiovascular ICU (CICU) after surgery.</p></sec><sec><label>3)</label><title>Postoperative administration</title><p>Upon return to the CICU, a standardized regimen for postoperative management was followed for all patients; they were started on one of the following two sedative protocols: dexmedetomidine (loading dose, 0.5 &#x003bc;g/kg; maintenance dose, 0.2 to 0.8 &#x003bc;g/kg/hr) or remifentanil (range, 1,000 to 2,500 &#x003bc;g/hr). Infusion rate of drugs was maintained by titration as per the specified protocol to maintain target sedation and adequate analgesia by specially trained nurses who were certified in cardiac intensive care. The efficacy measures for sedation and analgesia were based on the Modified Ramsay Sedation Scale (1&#x02013;6) and the Numeric Pain Intensity Scale (NPIS: 0&#x02013;10). We intended to maintain a Ramsay sedation score of 3 (before extubation) and 2 (after extubation). Additional analgesic agents (e.g., pethidine, morphine, or ketorolac) were applied if NPIS exceeded the grade of 7. The patients in both groups were extubated when clinically appropriate according to respiratory care protocols in CICU. The extubation time as well as the frequency of additional analgesics given was also documented methodically. If a patient developed delirium, haloperidol (5 mg) every 6 hours was administered as needed for agitation and not responding to adjustment of the assigned sedative drugs.</p></sec><sec><label>4)</label><title>Outcome measures</title><p>The primary outcome of the study was the proportion of delirium developed during the first 3 days after surgery as determined by the validated delirium instrument, confusion assessment method for ICU (CAM-ICU). The CAM-ICU is the most widely used instrument for diagnosing delirium by medical staff and non-psychiatrists and has been known to have the merits of ease, rapid assessment time, reliability, and validity. CAM-ICU yields a standardized judgment of delirium, which was validated against expert views and Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision [<xref rid="b11-kjtcvs-47-249" ref-type="bibr">11</xref>]. The study was designed to investigate postoperative delirium in the first 3 days because several other studies have reported that the highest incidence of postoperative delirium occurs during the first 3 postoperative days. CAM-ICU was performed once daily between 10:00 am and 12:00 noon (before midday). Abnormal or delirious behavior was recorded every turn-over by individually assigned nurses. Meanwhile, CAM-ICU was not performed in patients who had a Ramsay Sedation Score of 4 or higher (comatose state). Secondary outcomes included duration of ventilator support, length of ICU stay, length of hospital stay, and use of additional rescue medications. Additionally, clinical adverse events were documented in all patients, which were hypotension (defined as SBP less than 90 mmHg), bradycardia (defined as heart rate less than 55/min), re-intubation within 48 hours, and renal failure.</p></sec><sec><label>5)</label><title>Statistical analyses</title><p>Statistical analyses were performed with PASW SPSS ver. 18.0 (SPSS Inc., Chicago, IL, USA). Categorical variables are expressed as percentages or numbers, and continuous variables are expressed as means with standard deviations. After testing for normality of distribution, continuous variables were compared using the Student t-test. Categorical variables were compared using the chi-square test or Fisher&#x02019;s exact test. All p-values less than 0.05 were considered statistically significant.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>A majority of the patients underwent single cardiac valve surgery such as aortic valvuloplasty (AVP) and mitral valvuloplasty, and others including various types of combined valve surgery as well as AVP with coronary artery bypass grafting (CABG) surgery (<xref ref-type="table" rid="t1-kjtcvs-47-249">Table 1</xref>). Patients in both groups were statistically similar in terms of the preoperative demographic and baseline characteristics. CPB time, aortic cross-clamp time, intraoperative lowest temperature, the length of operation, and total anesthesia time were not significantly different between the two groups (<xref ref-type="table" rid="t2-kjtcvs-47-249">Table 2</xref>). The overall incidence of delirium during postoperative first 3 days was 16% (23 of 142), with 8.96% (6 of 67) occurring in the dexmedetomidine and 22.67% (17 of 75) in the remifentanil group, respectively (p&#x0003c;0.05). In postoperative outcomes, no statistically significant differences were observed between the two groups in the duration of mechanical ventilator support, ICU stay, total hospital stay, and other postoperative complications (p&#x0003e;0.05) (<xref ref-type="table" rid="t3-kjtcvs-47-249">Table 3</xref>). However, the number of patients requiring an additional infusion of analgesics such as pethidine and ketorolac was significantly higher in the dexmedetomidine group than in the remifentanil group.</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>The present study evaluated the administration of a highly selective &#x003b1;-2 agonist, dexmedetomidine focusing on cardiac postoperative care. The study concluded that sedation with dexmedetomidine was associated with a significantly reduced incidence of postoperative delirium in patients undergoing cardiac surgery with CPB. In general, cardiac surgery, particularly valve surgery, has a high risk of cardiovascular and other complications with a reported incidence of over 30%. Among others, the occurrence of postoperative cognitive dysfunction in patients undergoing cardiac surgery has been attributed to the synergistic effect of microemboli, hypoperfusion, and fast rewarming during CPB [<xref rid="b7-kjtcvs-47-249" ref-type="bibr">7</xref>,<xref rid="b8-kjtcvs-47-249" ref-type="bibr">8</xref>]. However, it is still obscure whether postoperative delirium or cognitive decline is actually related to CPB or not. As for the type of cardiac surgery, it has been known that patients undergoing valvular surgery are at a higher risk of delirium than CABG patients, which makes them potentially more vulnerable to postoperative neuropsychiatric deficits [<xref rid="b12-kjtcvs-47-249" ref-type="bibr">12</xref>]. Similarly, a majority of the patients considered in this study were cardiac valve surgery patients. The low prevalence of delirium in this study may be justified by the pre-exclusion of certain patients who had diagnosis of dementia or other psychological problems, psychotropic medication, and stroke history.</p><p>In addition, choices of sedatives in the postoperative period may be critical for preventing delirium. The highly sensitive &#x003b1;-2-adrenergic agonist, dexmedetomidine, has recently attracted considerable attention due to its ability to provide adequate postoperative sedation and analgesia without producing excessive hypotension or the need for vasopressors, while reducing the risk of delirium after cardiac surgery. Unlike conventional sedatives such as propofol, midazolam, or morphine, dexmedetomidine can produce anxiolysis and sedation without provoking significant respiratory depression. It seems that this respiratory advantage of dexmedetomidine is directly related to postoperative delirium, as other studies have implied that dexmedetomidine&#x02019;s effects on delirium are not simply due to its opioid-sparing properties [<xref rid="b13-kjtcvs-47-249" ref-type="bibr">13</xref>]. Several studies have reported that prolonged periods of intubation increase the risk of delirium by 1.10 to 7.90 times as compared to shorter periods of intubation [<xref rid="b14-kjtcvs-47-249" ref-type="bibr">14</xref>]. Consequently, dexmedetomidine has another potential advantage in that patients may be extubated in the sedated state and that they may be maintained under sedation as long as necessary until homeostasis is recovered and pain and anxiety are kept under control [<xref rid="b15-kjtcvs-47-249" ref-type="bibr">15</xref>]. These findings presume that the maximum benefit of dexmedetomidine may be realized in patients at a high risk of delayed extubation. A number of previous studies reported that less additional rescue medications for pain control were applied in the dexmedetomidine group, and shorter extubation time was found in this group. However, there were no statistical differences in the duration of intubated state, ICU stay, total hospital stay, and other postoperative complications between the two groups in this study. Besides, the number of patients requiring an additional infusion of analgesics (pethidine and ketorolac) was significantly higher in the dexmedetomidine group unlike the other reports. Therefore, it may be inferred that dexmedetomidine is inferior to remifentanil in terms of the analgesic effect. This is a challenging study evaluating the efficacy and safety of dexmedetomidine with respect to the reduction of postoperative delirium in adult cardiac surgery patients. There are several limitations of this clinical research. First, long-term neurocognitive function was not evaluated in this study and should be included in future research to determine the prognostic significance of delirium in the ICU on long-term cognitive outcomes. Secondly, reasonable rates of dexmedetomidine need to be validated by future extensive randomized studies to confirm the benefits of target agents. Thirdly, the study was conducted in a single medical center; therefore, there are limits to generalizing the results. Lastly, since CAM-ICU was estimated once daily for up to 3 days after surgery, it is possible that patients who appeared delirious after postoperative day 3 may have been missed, although this is likely to be insignificant.</p><p>In conclusion, dexmedetomidine administered as a postoperative sedative agent was associated with significantly lower rates of delirium after cardiac surgery with CPB. There were no statistically significant differences between the two groups in extubation time, ICU stay, total hospital stay, and other postoperative complications including hemodynamic side effects. However, the events requiring additional analgesics were significantly higher in the dexmedetomidine group than in the remifentanil group.</p></sec></body><back><fn-group><fn id="fn1-kjtcvs-47-249"><p><bold>CONFLICT OF INTEREST</bold></p><p>No potential conflict of interest relevant to this article was reported.</p></fn></fn-group><ref-list><title>REFERERENCES</title><ref id="b1-kjtcvs-47-249"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ely</surname><given-names>EW</given-names></name><name><surname>Shintani</surname><given-names>A</given-names></name><name><surname>Truman</surname><given-names>B</given-names></name><etal/></person-group><article-title>Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit</article-title><source>JAMA</source><year>2004</year><volume>291</volume><fpage>1753</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">15082703</pub-id></element-citation></ref><ref id="b2-kjtcvs-47-249"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebert</surname><given-names>AD</given-names></name><name><surname>Walzer</surname><given-names>TA</given-names></name><name><surname>Huth</surname><given-names>C</given-names></name><name><surname>Herrmann</surname><given-names>M</given-names></name></person-group><article-title>Early neurobehavioral disorders after cardiac surgery: a comparative analysis of coronary artery bypass graft surgery and valve replacement</article-title><source>J Cardiothorac Vasc Anesth</source><year>2001</year><volume>15</volume><fpage>15</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11254833</pub-id></element-citation></ref><ref id="b3-kjtcvs-47-249"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Keeffe</surname><given-names>S</given-names></name><name><surname>Lavan</surname><given-names>J</given-names></name></person-group><article-title>The prognostic significance of delirium in older hospital patients</article-title><source>J Am Geriatr Soc</source><year>1997</year><volume>45</volume><fpage>174</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9033515</pub-id></element-citation></ref><ref id="b4-kjtcvs-47-249"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Francis</surname><given-names>J</given-names></name><name><surname>Martin</surname><given-names>D</given-names></name><name><surname>Kapoor</surname><given-names>WN</given-names></name></person-group><article-title>A prospective study of delirium in hospitalized elderly</article-title><source>JAMA</source><year>1990</year><volume>263</volume><fpage>1097</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">2299782</pub-id></element-citation></ref><ref id="b5-kjtcvs-47-249"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rabinowitz</surname><given-names>T</given-names></name></person-group><article-title>Delirium: an important (but often unrecognized) clinical syndrome</article-title><source>Curr Psychiatry Rep</source><year>2002</year><volume>4</volume><fpage>202</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">12003683</pub-id></element-citation></ref><ref id="b6-kjtcvs-47-249"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maldonado</surname><given-names>JR</given-names></name></person-group><article-title>Delirium in the acute care setting: characteristics, diagnosis and treatment</article-title><source>Crit Care Clin</source><year>2008</year><volume>24</volume><fpage>657</fpage><lpage>722</lpage><comment>vii</comment><pub-id pub-id-type="pmid">18929939</pub-id></element-citation></ref><ref id="b7-kjtcvs-47-249"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bucerius</surname><given-names>J</given-names></name><name><surname>Gummert</surname><given-names>JF</given-names></name><name><surname>Borger</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Predictors of delirium after cardiac surgery delirium: effect of beating-heart (off-pump) surgery</article-title><source>J Thorac Cardiovasc Surg</source><year>2004</year><volume>127</volume><fpage>57</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">14752413</pub-id></element-citation></ref><ref id="b8-kjtcvs-47-249"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van der Mast</surname><given-names>RC</given-names></name><name><surname>van den Broek</surname><given-names>WW</given-names></name><name><surname>Fekkes</surname><given-names>D</given-names></name><name><surname>Pepplinkhuizen</surname><given-names>L</given-names></name><name><surname>Habbema</surname><given-names>JD</given-names></name></person-group><article-title>Incidence of and preoperative predictors for delirium after cardiac surgery</article-title><source>J Psychosom Res</source><year>1999</year><volume>46</volume><fpage>479</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">10404482</pub-id></element-citation></ref><ref id="b9-kjtcvs-47-249"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dasta</surname><given-names>JF</given-names></name><name><surname>Jacobi</surname><given-names>J</given-names></name><name><surname>Sesti</surname><given-names>AM</given-names></name><name><surname>McLaughlin</surname><given-names>TP</given-names></name></person-group><article-title>Addition of dexmedetomidine to standard sedation regimens after cardiac surgery: an outcomes analysis</article-title><source>Pharmacotherapy</source><year>2006</year><volume>26</volume><fpage>798</fpage><lpage>805</lpage><pub-id pub-id-type="pmid">16716133</pub-id></element-citation></ref><ref id="b10-kjtcvs-47-249"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venn</surname><given-names>RM</given-names></name><name><surname>Hell</surname><given-names>J</given-names></name><name><surname>Grounds</surname><given-names>RM</given-names></name></person-group><article-title>Respiratory effects of dexmedetomidine in the surgical patient requiring intensive care</article-title><source>Crit Care</source><year>2000</year><volume>4</volume><fpage>302</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">11056756</pub-id></element-citation></ref><ref id="b11-kjtcvs-47-249"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ely</surname><given-names>EW</given-names></name><name><surname>Inouye</surname><given-names>SK</given-names></name><name><surname>Bernard</surname><given-names>GR</given-names></name><etal/></person-group><article-title>Delirium in mechanically ventilated patients: validity and reliability of the confusion assessment method for the intensive care unit (CAM-ICU)</article-title><source>JAMA</source><year>2001</year><volume>286</volume><fpage>2703</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">11730446</pub-id></element-citation></ref><ref id="b12-kjtcvs-47-249"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vingerhoets</surname><given-names>G</given-names></name><name><surname>Van Nooten</surname><given-names>G</given-names></name><name><surname>Vermassen</surname><given-names>F</given-names></name><name><surname>De Soete</surname><given-names>G</given-names></name><name><surname>Jannes</surname><given-names>C</given-names></name></person-group><article-title>Short-term and long-term neuropsychological consequences of cardiac surgery with extracorporeal circulation</article-title><source>Eur J Cardiothorac Surg</source><year>1997</year><volume>11</volume><fpage>424</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">9105803</pub-id></element-citation></ref><ref id="b13-kjtcvs-47-249"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shehabi</surname><given-names>Y</given-names></name><name><surname>Grant</surname><given-names>P</given-names></name><name><surname>Wolfenden</surname><given-names>H</given-names></name><etal/></person-group><article-title>Prevalence of delirium with dexmedetomidine compared with morphine based therapy after cardiac surgery: a randomized controlled trial (DEXmedetomidine COmpared to Morphine-DEXCOM Study)</article-title><source>Anesthesiology</source><year>2009</year><volume>111</volume><fpage>1075</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">19786862</pub-id></element-citation></ref><ref id="b14-kjtcvs-47-249"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burns</surname><given-names>KD</given-names></name><name><surname>Jenkins</surname><given-names>W</given-names></name><name><surname>Yeh</surname><given-names>D</given-names></name><etal/></person-group><article-title>Delirium after cardiac surgery: a retrospective case-control study of incidence and risk factors in a Canadian sample</article-title><source>BC Med J</source><year>2009</year><volume>51</volume><fpage>206</fpage><lpage>10</lpage></element-citation></ref><ref id="b15-kjtcvs-47-249"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campos</surname><given-names>LA</given-names></name><name><surname>Soares</surname><given-names>LG</given-names></name><name><surname>Fernandes</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Immediate postoperative analgesia and sedation following heart surgery: a comparative analysis of dexmedetomidine chlorohydrate versus remifentanyl hydrochloride</article-title><source>Crit Care</source><year>2001</year><volume>5</volume><fpage>70</fpage></element-citation></ref></ref-list></back><floats-group><table-wrap id="t1-kjtcvs-47-249" position="float"><label>Table 1</label><caption><p>Types of operation</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" rowspan="1" colspan="1">Variable</th><th align="center" valign="middle" rowspan="1" colspan="1">Dexmedetomidine group (n=67)</th><th align="center" valign="middle" rowspan="1" colspan="1">Remifentanil group (n=75)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">AVP only</td><td align="center" valign="top" rowspan="1" colspan="1">34</td><td align="center" valign="top" rowspan="1" colspan="1">22</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AVP+MVP</td><td align="center" valign="top" rowspan="1" colspan="1">6</td><td align="center" valign="top" rowspan="1" colspan="1">13</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AVP+coronary artery bypass graft</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MVP only</td><td align="center" valign="top" rowspan="1" colspan="1">21</td><td align="center" valign="top" rowspan="1" colspan="1">30</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MVP+tricuspid annuloplasty</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">6</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-kjtcvs-47-249"><p>AVP, aortic valvuloplasty; MVP, mitral valvuloplasty.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-kjtcvs-47-249" position="float"><label>Table 2</label><caption><p>Preoperative characteristics and intraoperative details</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" rowspan="1" colspan="1">Characteristic</th><th align="center" valign="middle" rowspan="1" colspan="1">Dexmedetomidine group (n=67)</th><th align="center" valign="middle" rowspan="1" colspan="1">Remifentanil group (n=75)</th><th align="center" valign="middle" rowspan="1" colspan="1">p-value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Age (yr)</td><td align="center" valign="top" rowspan="1" colspan="1">51.09&#x000b1;16.10</td><td align="center" valign="top" rowspan="1" colspan="1">54.35&#x000b1;13.97</td><td align="center" valign="top" rowspan="1" colspan="1">0.199<xref ref-type="table-fn" rid="tfn3-kjtcvs-47-249">a)</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gender (male/female)</td><td align="center" valign="top" rowspan="1" colspan="1">39/28</td><td align="center" valign="top" rowspan="1" colspan="1">40/35</td><td align="center" valign="top" rowspan="1" colspan="1">0.559<xref ref-type="table-fn" rid="tfn4-kjtcvs-47-249">b)</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Body surface area (m<sup>2</sup>)</td><td align="center" valign="top" rowspan="1" colspan="1">1.68&#x000b1;0.20</td><td align="center" valign="top" rowspan="1" colspan="1">1.68&#x000b1;0.17</td><td align="center" valign="top" rowspan="1" colspan="1">0.993<xref ref-type="table-fn" rid="tfn3-kjtcvs-47-249">a)</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">New York Heart Association class III &#x00026; IV</td><td align="center" valign="top" rowspan="1" colspan="1">12 (17.91)</td><td align="center" valign="top" rowspan="1" colspan="1">12 (16)</td><td align="center" valign="top" rowspan="1" colspan="1">0.762<xref ref-type="table-fn" rid="tfn4-kjtcvs-47-249">b)</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Left ventricular ejection fraction (%)</td><td align="center" valign="top" rowspan="1" colspan="1">63.45&#x000b1;9.18</td><td align="center" valign="top" rowspan="1" colspan="1">60.45&#x000b1;11.58</td><td align="center" valign="top" rowspan="1" colspan="1">0.094<xref ref-type="table-fn" rid="tfn3-kjtcvs-47-249">a)</xref></td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Past history</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Diabetes mellitus</td><td align="center" valign="top" rowspan="1" colspan="1">8 (11.94)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (6.67)</td><td align="center" valign="top" rowspan="1" colspan="1">0.277<xref ref-type="table-fn" rid="tfn4-kjtcvs-47-249">b)</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Hypertension</td><td align="center" valign="top" rowspan="1" colspan="1">16 (23.88)</td><td align="center" valign="top" rowspan="1" colspan="1">21 (28.00)</td><td align="center" valign="top" rowspan="1" colspan="1">0.577<xref ref-type="table-fn" rid="tfn4-kjtcvs-47-249">b)</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Present smoking</td><td align="center" valign="top" rowspan="1" colspan="1">9 (13.43)</td><td align="center" valign="top" rowspan="1" colspan="1">9 (12)</td><td align="center" valign="top" rowspan="1" colspan="1">0.798<xref ref-type="table-fn" rid="tfn4-kjtcvs-47-249">b)</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Chronic obstructive pulmonary disease</td><td align="center" valign="top" rowspan="1" colspan="1">2 (2.99)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.221<xref ref-type="table-fn" rid="tfn5-kjtcvs-47-249">c)</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Chronic renal failure</td><td align="center" valign="top" rowspan="1" colspan="1">4 (5.97)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (2.67)</td><td align="center" valign="top" rowspan="1" colspan="1">0.421<xref ref-type="table-fn" rid="tfn5-kjtcvs-47-249">c)</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cardiopulmonary bypass time (min)</td><td align="center" valign="top" rowspan="1" colspan="1">159.55&#x000b1;56.55</td><td align="center" valign="top" rowspan="1" colspan="1">173.19&#x000b1;79.56</td><td align="center" valign="top" rowspan="1" colspan="1">0.237<xref ref-type="table-fn" rid="tfn3-kjtcvs-47-249">a)</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Aortic cross-clamping time (min)</td><td align="center" valign="top" rowspan="1" colspan="1">94.22&#x000b1;38.40</td><td align="center" valign="top" rowspan="1" colspan="1">97.01&#x000b1;45.24</td><td align="center" valign="top" rowspan="1" colspan="1">0.698<xref ref-type="table-fn" rid="tfn3-kjtcvs-47-249">a)</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lowest temperature (&#x000b0;C)</td><td align="center" valign="top" rowspan="1" colspan="1">26.27&#x000b1;0.73</td><td align="center" valign="top" rowspan="1" colspan="1">26.27&#x000b1;0.75</td><td align="center" valign="top" rowspan="1" colspan="1">0.977<xref ref-type="table-fn" rid="tfn3-kjtcvs-47-249">a)</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Length of anesthesia (min)</td><td align="center" valign="top" rowspan="1" colspan="1">406.87&#x000b1;92.63</td><td align="center" valign="top" rowspan="1" colspan="1">403.97&#x000b1;124.51</td><td align="center" valign="top" rowspan="1" colspan="1">0.877<xref ref-type="table-fn" rid="tfn3-kjtcvs-47-249">a)</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Length of operation (min)</td><td align="center" valign="top" rowspan="1" colspan="1">344.69&#x000b1;90.63</td><td align="center" valign="top" rowspan="1" colspan="1">344.84&#x000b1;119.20</td><td align="center" valign="top" rowspan="1" colspan="1">0.993<xref ref-type="table-fn" rid="tfn3-kjtcvs-47-249">a)</xref></td></tr></tbody></table><table-wrap-foot><fn id="tfn2-kjtcvs-47-249"><p>Values are presented as mean&#x000b1;standard deviation or number (%).</p></fn><fn id="tfn3-kjtcvs-47-249"><label>a)</label><p>By Student t-test.</p></fn><fn id="tfn4-kjtcvs-47-249"><label>b)</label><p>By chi-square test.</p></fn><fn id="tfn5-kjtcvs-47-249"><label>c)</label><p>By Fisher&#x02019;s exact test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-kjtcvs-47-249" position="float"><label>Table 3</label><caption><p>Postoperative outcome variables and adverse events</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" rowspan="1" colspan="1">Variable</th><th align="center" valign="middle" rowspan="1" colspan="1">Dexmedetomidine group (n=67)</th><th align="center" valign="middle" rowspan="1" colspan="1">Remifentanil group (n=75)</th><th align="center" valign="middle" rowspan="1" colspan="1">p-value</th></tr></thead><tbody><tr><td colspan="4" align="left" valign="top" rowspan="1">Delirium</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Incidence of delirium</td><td align="center" valign="top" rowspan="1" colspan="1">6 (8.96)</td><td align="center" valign="top" rowspan="1" colspan="1">17 (22.67)</td><td align="center" valign="top" rowspan="1" colspan="1">0.027<xref ref-type="table-fn" rid="tfn8-kjtcvs-47-249">b)</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Mean length of delirium (day)</td><td align="center" valign="top" rowspan="1" colspan="1">3.5&#x000b1;1.87</td><td align="center" valign="top" rowspan="1" colspan="1">3.76&#x000b1;4.13</td><td align="center" valign="top" rowspan="1" colspan="1">0.882<xref ref-type="table-fn" rid="tfn7-kjtcvs-47-249">a)</xref></td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Time variables</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Time to extubation (hr)</td><td align="center" valign="top" rowspan="1" colspan="1">22.72&#x000b1;26.36</td><td align="center" valign="top" rowspan="1" colspan="1">18.60&#x000b1;19.74</td><td align="center" valign="top" rowspan="1" colspan="1">0.299<xref ref-type="table-fn" rid="tfn7-kjtcvs-47-249">a)</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Intensive care unit length of stay (hr)</td><td align="center" valign="top" rowspan="1" colspan="1">67.71&#x000b1;48.41</td><td align="center" valign="top" rowspan="1" colspan="1">61.25&#x000b1;30.57</td><td align="center" valign="top" rowspan="1" colspan="1">0.353<xref ref-type="table-fn" rid="tfn7-kjtcvs-47-249">a)</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Hospital length of stay (day)</td><td align="center" valign="top" rowspan="1" colspan="1">19.96&#x000b1;11.76</td><td align="center" valign="top" rowspan="1" colspan="1">18.37&#x000b1;8.45</td><td align="center" valign="top" rowspan="1" colspan="1">0.364<xref ref-type="table-fn" rid="tfn7-kjtcvs-47-249">a)</xref></td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Additional rescue medications</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Pethidine HCl</td><td align="center" valign="top" rowspan="1" colspan="1">14 (20.9)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.027<xref ref-type="table-fn" rid="tfn8-kjtcvs-47-249">b)</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Morphine sulfate</td><td align="center" valign="top" rowspan="1" colspan="1">1 (1.49)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (1.33)</td><td align="center" valign="top" rowspan="1" colspan="1">1.000<xref ref-type="table-fn" rid="tfn8-kjtcvs-47-249">b)</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Ketorolac tromethamine</td><td align="center" valign="top" rowspan="1" colspan="1">15 (22.39)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (4.00)</td><td align="center" valign="top" rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="tfn8-kjtcvs-47-249">b)</xref></td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Additional medications for delirium</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Haloperidol</td><td align="center" valign="top" rowspan="1" colspan="1">4 (5.97)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (5.33)</td><td align="center" valign="top" rowspan="1" colspan="1">0.869<xref ref-type="table-fn" rid="tfn8-kjtcvs-47-249">b)</xref></td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Postoperative adverse events</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Bradycardia (heart rate&#x0003c;55)</td><td align="center" valign="top" rowspan="1" colspan="1">10 (14.9)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (10.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.446<xref ref-type="table-fn" rid="tfn8-kjtcvs-47-249">b)</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Systolic hypotension (systolic blood pressure&#x0003c;90 mmHg)</td><td align="center" valign="top" rowspan="1" colspan="1">12 (17.91)</td><td align="center" valign="top" rowspan="1" colspan="1">22 (29.33)</td><td align="center" valign="top" rowspan="1" colspan="1">0.111<xref ref-type="table-fn" rid="tfn8-kjtcvs-47-249">b)</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Atrial fibrillation</td><td align="center" valign="top" rowspan="1" colspan="1">5 (7.46)</td><td align="center" valign="top" rowspan="1" colspan="1">11 (14.67)</td><td align="center" valign="top" rowspan="1" colspan="1">0.175<xref ref-type="table-fn" rid="tfn8-kjtcvs-47-249">b)</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Atrioventricular dissociation</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">1 (1.33)</td><td align="center" valign="top" rowspan="1" colspan="1">1.000<xref ref-type="table-fn" rid="tfn8-kjtcvs-47-249">b)</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Acute renal failure</td><td align="center" valign="top" rowspan="1" colspan="1">2 (2.99)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (1.33)</td><td align="center" valign="top" rowspan="1" colspan="1">0.602<xref ref-type="table-fn" rid="tfn8-kjtcvs-47-249">b)</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Cerebrovascular accident</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">2 (2.67)</td><td align="center" valign="top" rowspan="1" colspan="1">0.498<xref ref-type="table-fn" rid="tfn8-kjtcvs-47-249">b)</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Pneumonia</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">1 (1.33)</td><td align="center" valign="top" rowspan="1" colspan="1">1.000<xref ref-type="table-fn" rid="tfn8-kjtcvs-47-249">b)</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Reintubation</td><td align="center" valign="top" rowspan="1" colspan="1">1 (1.49)</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0.471<xref ref-type="table-fn" rid="tfn8-kjtcvs-47-249">b)</xref></td></tr></tbody></table><table-wrap-foot><fn id="tfn6-kjtcvs-47-249"><p>Values are presented as number (%) or mean&#x000b1;standard deviation.</p></fn><fn id="tfn7-kjtcvs-47-249"><label>a)</label><p>By Student t-test.</p></fn><fn id="tfn8-kjtcvs-47-249"><label>b)</label><p>By chi-square test.</p></fn></table-wrap-foot></table-wrap></floats-group></article>